Identification

Name
Mirabegron
Accession Number
DB08893  (DB05702)
Type
Small Molecule
Groups
Approved
Description

Mirabegron is a beta-3 adrenergic receptor agonist for the management of overactive bladder. It is an alternative to antimuscarinic drugs for this indication. FDA approved on June 28, 2012.

Structure
Thumb
Synonyms
Not Available
External IDs
YM-178 / YM178
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe Bv2012-12-20Not applicableEu
International/Other Brands
Betanis / Metmiga / Myrbetriq
Categories
UNII
MVR3JL3B2V
CAS number
223673-61-8
Weight
Average: 396.506
Monoisotopic: 396.161996722
Chemical Formula
C21H24N4O2S
InChI Key
PBAPPPCECJKMCM-IBGZPJMESA-N
InChI
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
IUPAC Name
2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
SMILES
NC1=NC(CC(=O)NC2=CC=C(CCNC[[email protected]](O)C3=CC=CC=C3)C=C2)=CS1

Pharmacology

Indication

Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Structured Indications
Pharmacodynamics

Mirabegron has little effect on the mean maximum flow rate or mean detrusor pressure at maximum flow rate in patients with lower urinary tract symptoms and bladder outlet obstruction. Furthermore, mirabegron increases blood pressure in a dose dependent manner. However, this effect is reversible when mirabegron is discontinued. Mirabegron also increases heart rate in a dose dependent manner. The dose in which half-maximal efficacy is demonstrated is 25 mg. Comparatively, the dose in which maximal efficacy is demonstrated is 100 mg.

Mechanism of action

Mirabegron is a potent and selective agonist for beta-3 adrenergic receptors. Once beta-3 receptors are activated, the detrusor smooth muscle relaxes to allow for a larger bladder capacity. At higher doses (200 mg), there is a potential for mirabegron to activate beta-1 and beta-2 adrenergic receptors.

TargetActionsOrganism
ABeta-3 adrenergic receptor
agonist
Human
Absorption

The absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose. Tmax, oral dose, healthy subjects= 3.5 hours;

Volume of distribution

Vd, steady state, IV dose = 1670 L. This high value suggests that mirabegron is extensively distributed in the body.

Protein binding

71% bound to plasma proteins. It binds to albumin and alpha-1-acid glycoprotein with moderate affinity.

Metabolism

Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. The major circulating entity is mirabegron. Two major and inactive metabolites (phase 2 glucuronides) are produced. Although mirabegron is a substrate for CYP2D6 and CYP3A4, its role in the elimination of the drug is limited. Studies also suggest that CYP3A4 is the main enzyme that facilitates the oxidative metabolism of the drug. Furthermore, butylcholinesterase, uridine diphospho-glucuronosyltransferases (UGT), and possibly alcohol dehydrogenase may be involved with the metabolism of mirabegron.

Route of elimination

Mirabegron is eliminated via urine (radiolabeled drug: 55%; unchanged drug: ~25%) and feces (radiolabeled drug: 34%; unchanged drug: 0%). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Extent of elimination via urine is dose-dependent.

Half life

Terminal elimination half-life = 50 hours

Clearance

Total body clearance (CLtot), IV dose = 57 L/h; Renal clearance (CLR) = 13 L/h

Toxicity

Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Mirabegron.Experimental, Illicit
AbirateroneThe serum concentration of Mirabegron can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Mirabegron.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Mirabegron.Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Mirabegron.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Mirabegron.Approved, Investigational
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Mirabegron.Experimental
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Mirabegron.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Mirabegron.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Mirabegron.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Mirabegron.Approved, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Mirabegron.Approved, Withdrawn
AmiodaroneThe metabolism of Mirabegron can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Mirabegron.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Mirabegron.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Mirabegron.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Mirabegron.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Mirabegron.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mirabegron.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Mirabegron.Approved
AprepitantThe serum concentration of Mirabegron can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Mirabegron.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Mirabegron.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.Approved, Investigational
ArtemetherThe metabolism of Mirabegron can be decreased when combined with Artemether.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Mirabegron.Approved, Withdrawn
AtazanavirThe metabolism of Mirabegron can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Mirabegron can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Mirabegron.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mirabegron.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mirabegron.Approved, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Mirabegron.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Mirabegron.Withdrawn
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mirabegron.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Mirabegron.Approved
Benzylpenicilloyl PolylysineMirabegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Mirabegron.Approved, Withdrawn
BetaxololThe metabolism of Mirabegron can be decreased when combined with Betaxolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Mirabegron.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Mirabegron.Approved
BoceprevirThe metabolism of Mirabegron can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Mirabegron.Experimental
BortezomibThe metabolism of Mirabegron can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Mirabegron can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Mirabegron.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Mirabegron.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Mirabegron.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Mirabegron.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Mirabegron.Experimental, Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Mirabegron.Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Mirabegron.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Mirabegron.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Mirabegron can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Mirabegron.Approved, Investigational
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Mirabegron.Approved, Vet Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Mirabegron.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Mirabegron.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Mirabegron.Approved
CarbamazepineThe metabolism of Mirabegron can be increased when combined with Carbamazepine.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Mirabegron.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Mirabegron.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Mirabegron.Approved, Investigational
CelecoxibThe metabolism of Mirabegron can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Mirabegron.Approved, Vet Approved
CeritinibThe serum concentration of Mirabegron can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Mirabegron.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Mirabegron.Approved, Illicit
ChloroquineThe metabolism of Mirabegron can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Mirabegron.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Mirabegron.Withdrawn
ChlorpromazineThe metabolism of Mirabegron can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Mirabegron.Approved
CholecalciferolThe metabolism of Mirabegron can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Mirabegron.Approved
CimetidineThe metabolism of Mirabegron can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Mirabegron can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Mirabegron.Approved, Investigational
CitalopramThe metabolism of Mirabegron can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Mirabegron can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Mirabegron can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Mirabegron.Approved
ClobazamThe metabolism of Mirabegron can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Mirabegron can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Mirabegron.Approved
ClotrimazoleThe metabolism of Mirabegron can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Mirabegron can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Mirabegron can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Mirabegron can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Mirabegron.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Mirabegron.Approved, Investigational
CrizotinibThe metabolism of Mirabegron can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mirabegron.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Mirabegron.Approved, Investigational
CyclosporineThe metabolism of Mirabegron can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Mirabegron.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron.Approved, Investigational
DarunavirThe serum concentration of Mirabegron can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Mirabegron.Approved
DasatinibThe serum concentration of Mirabegron can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Mirabegron.Approved, Investigational
DeferasiroxThe serum concentration of Mirabegron can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Mirabegron can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Mirabegron.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mirabegron.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Mirabegron.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Mirabegron.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mirabegron.Withdrawn
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Mirabegron.Approved, Illicit, Investigational, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Mirabegron.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Mirabegron.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Mirabegron.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mirabegron.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Mirabegron.Approved, Illicit
DihydroergotamineThe metabolism of Mirabegron can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Mirabegron can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Mirabegron can be decreased when combined with Diphenhydramine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Mirabegron.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Mirabegron.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Mirabegron.Approved
DosulepinThe metabolism of Mirabegron can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Mirabegron.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Mirabegron.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mirabegron.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Mirabegron.Approved, Investigational
DoxycyclineThe metabolism of Mirabegron can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Mirabegron can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Mirabegron can be decreased when combined with Duloxetine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Mirabegron.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Mirabegron.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Mirabegron.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Mirabegron.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Mirabegron.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Mirabegron.Investigational
EnzalutamideThe serum concentration of Mirabegron can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Mirabegron.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Mirabegron.Approved, Investigational
ErythromycinThe metabolism of Mirabegron can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Mirabegron.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Mirabegron.Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Mirabegron.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Mirabegron.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Mirabegron.Approved, Illicit
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Mirabegron.Approved, Investigational
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Mirabegron.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Mirabegron.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Mirabegron.Approved, Withdrawn
FluconazoleThe metabolism of Mirabegron can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Mirabegron.Approved
FluoxetineThe metabolism of Mirabegron can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Mirabegron.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Mirabegron.Approved
FluvoxamineThe metabolism of Mirabegron can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Mirabegron.Approved, Investigational
FosamprenavirThe metabolism of Mirabegron can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mirabegron can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Mirabegron can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Mirabegron can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Mirabegron.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Mirabegron.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mirabegron.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Mirabegron.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Mirabegron.Approved, Investigational, Vet Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Mirabegron.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Mirabegron.Approved
HaloperidolThe metabolism of Mirabegron can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Mirabegron.Approved, Vet Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Mirabegron.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Mirabegron.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Mirabegron.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Mirabegron.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mirabegron.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Mirabegron.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Mirabegron.Approved
IdelalisibThe metabolism of Mirabegron can be decreased when combined with Idelalisib.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Mirabegron.Approved
ImatinibThe metabolism of Mirabegron can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Mirabegron can be decreased when combined with Imipramine.Approved
IndinavirThe metabolism of Mirabegron can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Mirabegron.Withdrawn
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.Approved
IsavuconazoniumThe metabolism of Mirabegron can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Mirabegron can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Mirabegron can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Mirabegron can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mirabegron can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Mirabegron.Approved
KetoconazoleThe serum concentration of Mirabegron can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Mirabegron.Approved
LetermovirThe metabolism of Letermovir can be decreased when combined with Mirabegron.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Mirabegron.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Mirabegron.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Mirabegron.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Mirabegron.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Mirabegron.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Mirabegron.Approved
LopinavirThe metabolism of Mirabegron can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Mirabegron.Approved
LorcaserinThe metabolism of Mirabegron can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Mirabegron can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Mirabegron can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Mirabegron can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Mirabegron can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Mirabegron can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Mirabegron.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Mirabegron.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Mirabegron.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Mirabegron.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Mirabegron.Approved, Investigational
MethadoneThe metabolism of Mirabegron can be decreased when combined with Methadone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Mirabegron.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Mirabegron.Approved, Investigational
MethotrimeprazineThe metabolism of Mirabegron can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Mirabegron.Approved
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Mirabegron.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Mirabegron.Approved, Investigational
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Mirabegron.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Mirabegron.Approved, Illicit, Withdrawn
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Mirabegron.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Mirabegron.Approved, Investigational
MetoprololMirabegron may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Mirabegron.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Mirabegron.Approved, Investigational
MidostaurinThe metabolism of Mirabegron can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Mirabegron can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Mirabegron can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Mirabegron.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Mirabegron.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Mirabegron.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Mirabegron.Approved, Investigational
NefazodoneThe metabolism of Mirabegron can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Mirabegron can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Mirabegron can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Mirabegron can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Mirabegron can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Mirabegron.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Mirabegron.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Mirabegron.Approved
NilotinibThe metabolism of Mirabegron can be decreased when combined with Nilotinib.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Mirabegron.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Mirabegron.Approved, Investigational
OlaparibThe metabolism of Mirabegron can be decreased when combined with Olaparib.Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Mirabegron.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mirabegron.Approved
OsimertinibThe serum concentration of Mirabegron can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Mirabegron.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Mirabegron.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mirabegron.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Mirabegron.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mirabegron.Approved
PalbociclibThe serum concentration of Mirabegron can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Mirabegron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Mirabegron.Approved
PanobinostatThe serum concentration of Mirabegron can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Mirabegron can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Mirabegron.Approved
Peginterferon alfa-2bThe serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Mirabegron.Approved
PentobarbitalThe metabolism of Mirabegron can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Mirabegron.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Mirabegron.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Mirabegron.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Mirabegron.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Mirabegron.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Mirabegron.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Mirabegron.Approved, Investigational, Withdrawn
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Mirabegron.Experimental
PhenobarbitalThe metabolism of Mirabegron can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Mirabegron can be increased when combined with Phenytoin.Approved, Vet Approved
PindololThe metabolism of Pindolol can be decreased when combined with Mirabegron.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Mirabegron.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Mirabegron.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Mirabegron.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Mirabegron.Approved
PosaconazoleThe metabolism of Mirabegron can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Mirabegron.Approved
PrimidoneThe metabolism of Mirabegron can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Mirabegron.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Mirabegron.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mirabegron.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Mirabegron.Approved, Vet Approved
PromazineThe metabolism of Mirabegron can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Mirabegron.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Mirabegron.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Mirabegron.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Mirabegron.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Mirabegron.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Mirabegron.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Mirabegron.Approved
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Mirabegron.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mirabegron.Approved
QuinineThe metabolism of Mirabegron can be decreased when combined with Quinine.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Mirabegron.Approved
RanolazineThe serum concentration of Mirabegron can be increased when it is combined with Ranolazine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Mirabegron.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Mirabegron.Investigational
RifabutinThe metabolism of Mirabegron can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Mirabegron can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Mirabegron can be increased when combined with Rifapentine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Mirabegron.Approved, Investigational
RitonavirThe metabolism of Mirabegron can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Mirabegron can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Mirabegron can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Mirabegron.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Mirabegron.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Mirabegron.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Mirabegron.Approved
SaquinavirThe metabolism of Mirabegron can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Mirabegron can be decreased when used in combination with Sarilumab.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Mirabegron.Approved, Investigational, Withdrawn
SertralineThe metabolism of Mirabegron can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Mirabegron can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Mirabegron.Approved
SiltuximabThe serum concentration of Mirabegron can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Mirabegron can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Mirabegron.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Mirabegron is combined with Solifenacin.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Mirabegron.Experimental
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Mirabegron.Approved
St. John's WortThe serum concentration of Mirabegron can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Mirabegron can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Mirabegron can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Mirabegron resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Mirabegron.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Mirabegron.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Mirabegron.Investigational, Withdrawn
TelaprevirThe metabolism of Mirabegron can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Mirabegron can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Mirabegron.Approved
TerbinafineThe metabolism of Mirabegron can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Mirabegron.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Mirabegron.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Mirabegron.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Mirabegron.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mirabegron.Approved, Withdrawn
TiclopidineThe metabolism of Mirabegron can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Mirabegron.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Mirabegron.Approved
TipranavirThe metabolism of Mirabegron can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Mirabegron can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Mirabegron.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Mirabegron.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Mirabegron.Approved, Investigational
TranylcypromineThe metabolism of Mirabegron can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Mirabegron.Approved, Investigational
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mirabegron.Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Mirabegron.Experimental
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Mirabegron.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Mirabegron.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Mirabegron.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mirabegron.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mirabegron.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Mirabegron.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Mirabegron.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Mirabegron.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Mirabegron.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.Approved
VemurafenibThe serum concentration of Mirabegron can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Mirabegron can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Mirabegron can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Mirabegron.Approved, Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Mirabegron.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Mirabegron.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Mirabegron.Approved, Investigational
VoriconazoleThe metabolism of Mirabegron can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Mirabegron.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Mirabegron.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Mirabegron.Approved, Investigational
ZiprasidoneThe metabolism of Mirabegron can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Mirabegron.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Mirabegron.Approved, Investigational
Food Interactions
  • When taken with meals, levels of mirabegron decreased. Furthermore, the magnitude of this effect was greater if taken with a low fat meal, rather than a high fat meal. Despite these findings, dose adjustment is not required.

References

General References
  1. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O: Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007 May;321(2):642-7. Epub 2007 Feb 9. [PubMed:17293563]
  2. Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899]
External Links
KEGG Drug
D09535
PubChem Compound
9865528
PubChem Substance
175427137
ChemSpider
8041219
ChEBI
65349
ChEMBL
CHEMBL2095212
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mirabegron
ATC Codes
G04BD12 — Mirabegron
AHFS Codes
  • 86:12.08.12 — Selective Beta 3-adrenergic Agonists
FDA label
Download (510 KB)
MSDS
Download (481 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingBasic ScienceMetabolic Syndromes / Obese1
1CompletedNot AvailableBioavailability / Healthy Volunteers / Pharmacokinetics of Mirabegron1
1CompletedNot AvailableCardiovascular / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHealthy Chinese Volunteers1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Mirabegron4
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of YM1783
1CompletedNot AvailableHealthy Volunteers / Plasma Concentration of Mirabegron1
1CompletedNot AvailableImpaired Renal Function1
1CompletedNot AvailableIntraocular Pressure1
1CompletedNot AvailablePharmacokinetics of YM1781
1CompletedBasic ScienceBioavailability / Healthy Volunteers / Phase 11
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics2
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Mild and Moderate Hepatic Impairment / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics of Mirabegron1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Mirabegron3
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of YM1781
1CompletedBasic ScienceMetabolic Processes1
1CompletedBasic ScienceNeurogenic Detrusor Overactivity / Overactive Bladder1
1CompletedBasic ScienceNeurogenic Detrusor Overactivity / Overactive Bladder / Pharmacokinetics of Mirabegron1
1CompletedBasic ScienceOveractive Bladder / Pharmacokinetics1
1RecruitingBasic ScienceHealthy Volunteers1
1, 2RecruitingTreatmentErectile Dysfunction (ED) / Overactive Bladder / Urinary Incontinence (UI)1
2CompletedTreatmentBladder Outlet Obstruction / Lower Urinary Tract Symptoms (LUTS)1
2CompletedTreatmentEssential Thrombocythemia (ET) / Myeloproliferative Neoplasms / Polycythemia Vera (PV) / Primary Myelofibrosis1
2CompletedTreatmentOveractive Bladder1
2CompletedTreatmentSigns and Symptoms / Urinary Bladder Diseases / Urinary Bladder, Overactive / Urologic Diseases / Urological Manifestations1
2CompletedTreatmentUrinary Bladder, Overactive2
2Enrolling by InvitationTreatmentLeft Ventricular Hypertrophy1
2Not Yet RecruitingTreatmentFlank Pain / Ureteral Obstruction1
2Not Yet RecruitingTreatmentHeart Failure, Unspecified / Mirabegron / Pulmonary Hypertension (PH) / Pulmonary vascular resistance abnormality1
2Not Yet RecruitingTreatmentSpinal Cord Injuries (SCI) / Urinary Bladder, Neurogenic1
2RecruitingBasic ScienceBrown Fat1
2RecruitingTreatmentAutonomic Dysreflexia / Autonomic Integrity / Baroreceptor Integrity / Blood Pressures / Cerebral Blood Flow / Cognitive Function / Hypotensive / Spinal Cord Injuries (SCI) / Sympathetic Integrity / Vagal Integrity1
2RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
2RecruitingTreatmentLower Urinary Tract Symptoms (LUTS) / Pain / Urinary Bladder, Overactive1
2, 3Enrolling by InvitationTreatmentUrinary Bladder, Neurogenic1
3CompletedTreatmentOveractive Bladder Syndrome / Urinary Incontinence (UI)1
3CompletedTreatmentOveractive Bladder / Urgency Incontinence / Urinary Bladder Diseases\Urologic Diseases / Urinary Bladder Overactive2
3CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)2
3CompletedTreatmentUrinary Bladder Diseases / Urinary Bladder Overactive / Urologic Diseases1
3CompletedTreatmentUrinary Bladder Diseases / Urinary Bladder, Overactive / Urologic Diseases1
3CompletedTreatmentUrinary Bladder, Overactive7
3RecruitingTreatmentInterstitial Cystitis1
3RecruitingTreatmentNeurogenic Detrusor Overactivity1
3RecruitingTreatmentOveractive Bladder Syndrome1
4Active Not RecruitingTreatmentOveractive Bladder1
4Active Not RecruitingTreatmentOveractive Bladder (OAB)1
4CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Mirabegron and Tolterodine1
4CompletedNot AvailableOveractive Bladder1
4CompletedTreatmentOveractive Bladder1
4CompletedTreatmentOveractive Bladder (OAB)2
4Not Yet RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Overactive Bladder1
4Not Yet RecruitingTreatmentBladder Irritable / Bladder Pain Syndrome / Urinary Frequency/Urgency1
4Not Yet RecruitingTreatmentOveractive Bladder1
4RecruitingTreatmentBMI >30 kg/m21
4RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Overactive Bladder1
4RecruitingTreatmentCalcium Nephrolithiasis1
4RecruitingTreatmentDisseminated Sclerosis1
4RecruitingTreatmentImpaired Cognition / Overactive Bladder / Parkinson's Disease (PD)1
4RecruitingTreatmentOveractive Bladder1
4RecruitingTreatmentOveractive Bladder Syndrome1
4RecruitingTreatmentParkinsons's Disease1
4RecruitingTreatmentUrge Incontinence / Urinary Incontinence, Urge1
4Unknown StatusTreatmentOveractive Bladder1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Overactive Bladder1
Not AvailableCompletedNot AvailableOveractive Bladder2
Not AvailableCompletedNot AvailableOveractive Bladder / Urgency Incontinence / Urinary Bladder Diseases / Urinary Bladder Overactive / Urologic Diseases1
Not AvailableCompletedNot AvailableOveractive Bladder / Urinary Bladder Diseases / Urinary Bladder Overactive / Urologic Diseases1
Not AvailableNot Yet RecruitingTreatmentOveractive Bladder1
Not AvailableRecruitingNot AvailableLower Urinary Tract Symptoms (LUTS) / Nocturia1
Not AvailableRecruitingNot AvailableOveractive Bladder1
Not AvailableRecruitingOtherType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral25 mg
Tablet, extended releaseOral50 mg
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral50 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2305802No2008-11-182018-10-15Canada
CA2464068No2007-10-162022-10-29Canada
CA2503570No2023-11-042011-04-19Canada
USRE44872No2003-12-182023-12-18Us
US7750029No2003-12-182023-12-18Us
US6346532No1998-10-152018-10-15Us
US8835474No2003-11-042023-11-04Us
US6562375No2000-08-012020-08-01Us
US7982049No2003-11-042023-11-04Us
US7342117No2003-11-042023-11-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00412 mg/mLALOGPS
logP2.2ALOGPS
logP2.89ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area100.27 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity113.23 m3·mol-1ChemAxon
Polarizability44.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9398
Blood Brain Barrier+0.8115
Caco-2 permeable-0.6462
P-glycoprotein substrateSubstrate0.5567
P-glycoprotein inhibitor INon-inhibitor0.8492
P-glycoprotein inhibitor IINon-inhibitor0.8487
Renal organic cation transporterNon-inhibitor0.7223
CYP450 2C9 substrateNon-substrate0.7656
CYP450 2D6 substrateNon-substrate0.7786
CYP450 3A4 substrateNon-substrate0.641
CYP450 1A2 substrateNon-inhibitor0.5904
CYP450 2C9 inhibitorInhibitor0.6156
CYP450 2D6 inhibitorNon-inhibitor0.8873
CYP450 2C19 inhibitorNon-inhibitor0.574
CYP450 3A4 inhibitorInhibitor0.5223
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5711
Ames testNon AMES toxic0.6422
CarcinogenicityNon-carcinogens0.8972
BiodegradationNot ready biodegradable0.5977
Rat acute toxicity2.4527 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9094
hERG inhibition (predictor II)Inhibitor0.567
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004j-0429000000-a1fa6e47b60253c53578

Taxonomy

Description
This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Anilides
Alternative Parents
Phenethylamines / N-arylamides / 2,4-disubstituted thiazoles / Aralkylamines / 2-amino-1,3-thiazoles / Heteroaromatic compounds / 1,2-aminoalcohols / Amino acids and derivatives / Secondary alcohols / Secondary carboxylic acid amides
show 8 more
Substituents
Phenethylamine / Anilide / N-arylamide / 2,4-disubstituted 1,3-thiazole / Aralkylamine / 1,3-thiazol-2-amine / Azole / Thiazole / Heteroaromatic compound / 1,2-aminoalcohol
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid amide, 1,3-thiazole, aromatic amide, ethanolamines (CHEBI:65349)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188]
  2. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188]
  2. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393]

Drug created on May 30, 2013 23:44 / Updated on January 15, 2018 08:57